Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $227.8 million versus the consensus estimate of $220 million.

Sees FY17 revenues and EPS at high end of range.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c